Pages that link to "Q40461021"
Jump to navigation
Jump to search
The following pages link to Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. (Q40461021):
Displaying 50 items.
- Structure of the extracellular domains of human and Xenopus Fn14: implications in the evolution of TWEAK and Fn14 interactions (Q24320262) (← links)
- Principles of antibody-mediated TNF receptor activation (Q26796270) (← links)
- Protein microarrays, biosensors, and cell-based methods for secretome-wide extracellular protein-protein interaction mapping (Q27000402) (← links)
- Factors regulating immunoglobulin production by normal and disease-associated plasma cells (Q27021855) (← links)
- Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo (Q27314650) (← links)
- Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture Mechanism (Q27667288) (← links)
- Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival (Q28743862) (← links)
- BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis (Q30724766) (← links)
- Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice (Q33368623) (← links)
- Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo (Q33408460) (← links)
- Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL (Q33559757) (← links)
- The function of BAFF on T helper cells in autoimmunity (Q33748041) (← links)
- APRIL mediates peritoneal B-1 cell homeostasis (Q33758475) (← links)
- B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. (Q34159016) (← links)
- Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity (Q34575855) (← links)
- Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease (Q35452032) (← links)
- γ-Secretase directly sheds the survival receptor BCMA from plasma cells (Q35814239) (← links)
- Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome (Q35840812) (← links)
- The design and characterization of receptor-selective APRIL variants (Q36347872) (← links)
- An APRIL to remember: novel TNF ligands as therapeutic targets (Q36394955) (← links)
- Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials (Q36484465) (← links)
- Understanding cytokine and growth factor receptor activation mechanisms (Q36509470) (← links)
- Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. (Q36530420) (← links)
- Binding efficiency of protein-protein complexes (Q36595042) (← links)
- B-cell survival and development controlled by the coordination of NF-κB family members RelB and cRel. (Q36675058) (← links)
- APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa (Q36749700) (← links)
- The BLyS family: toward a molecular understanding of B cell homeostasis (Q37335169) (← links)
- Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. (Q37347235) (← links)
- Cracking the BAFF code. (Q37517172) (← links)
- Differential expression of BAFF and its receptors in discoid lupus erythematosus patients (Q37624045) (← links)
- Beyond transitional selection: New roles for BLyS in peripheral tolerance (Q37983058) (← links)
- BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus. (Q38013996) (← links)
- Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy (Q38095862) (← links)
- The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity (Q38107660) (← links)
- Aberrant B cell selection and activation in systemic lupus erythematosus (Q38114501) (← links)
- Behçet's syndrome pathophysiology and potential therapeutic targets (Q38177749) (← links)
- Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development? (Q38184585) (← links)
- New roles for the BLyS/BAFF family in antigen-experienced B cell niches (Q38186321) (← links)
- B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? (Q38365867) (← links)
- B cells biology in systemic lupus erythematosus-from bench to bedside. (Q38631964) (← links)
- Lupus nephritis and B-cell targeting therapy. (Q38643755) (← links)
- Development of a Novel BAFF Responsive Cell Line Suitable for Detecting Bioactive BAFF and Neutralizing Antibodies against BAFF-Pathway Inhibiting Therapeutics (Q38673541) (← links)
- Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. (Q38755707) (← links)
- Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells (Q38771001) (← links)
- A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells (Q39537457) (← links)
- Neutralization of Clostridium difficile toxin A using antibody combinations (Q39664838) (← links)
- Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells (Q39785651) (← links)
- Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinity. (Q40192267) (← links)
- Analysis of the regulatory role of BAFF in controlling the expression of CD21 and CD23. (Q41762909) (← links)
- Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies (Q41838529) (← links)